Research menu
Jump to menu

Publications:  Prof Morris Brown

Williams B, Brown MJ(2018). Investigation of primary aldosteronism in patients with resistant hypertension - Authors' reply. Lancet Diabetes Endocrinol vol. 6, (8) 600-601.
Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, Ford I, Cruickshank JK et al.(2018). Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol vol. 6, (6) 464-475.
BROWN MJ(2018). Investigation of the endocrine and haemodynamic changes in resistant hypertension, and its response to spironolactone or amiloride: the PATHWAY-2 mechanisms study. Lancet Diabetes and Endocrinology vol. 6, (6) 464-475.
MacDonald TM, Williams B, Webb DJ, Morant S, Caulfield M, Cruickshank JK, Ford I, Sever P et al.(2017). Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial. J Am Heart Assoc vol. 6, (11)
Maniero C, Garg S, Zhao W, Johnson TI, Zhou J, Gurnell M, Brown MJ(2017). NEFM (Neurofilament Medium) Polypeptide, a Marker for Zona Glomerulosa Cells in Human Adrenal, Inhibits D1R (Dopamine D1 Receptor)-Mediated Secretion of Aldosterone. Hypertension vol. 70, (2) 357-364.
Brown MJ(2017). Rapid Diagnosis of Primary Aldosteronism: Oxymoron or One Small Step?. Hypertension vol. 70, (2) 247-249.
Teo AED, Garg S, Johnson TI, Zhao W, Zhou J, Gomez-Sanchez CE, Gurnell M, Brown MJ(2017). Physiological and Pathological Roles in Human Adrenal of the Glomeruli-Defining Matrix Protein NPNT (Nephronectin). Hypertension vol. 69, (6) 1207-1216.
Bogman K, Schwab D, Delporte M-L, Palermo G, Amrein K, Mohr S, De Vera Mudry MC, Brown MJ et al.(2017). Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2). Hypertension vol. 69, (1) 189-196.
Brown MJ, Drake WM(2016). Primary aldosteronism as a public health issue - Authors' reply. Lancet Diabetes Endocrinol vol. 4, (12) 973-974.
Zhou J, Lam B, Neogi SG, Yeo GSH, Azizan EAB, Brown MJ(2016). Transcriptome Pathway Analysis of Pathological and Physiological Aldosterone-Producing Human Tissues. Hypertension vol. 68, (6) 1424-1431.
Brown MJ, Drake WM(2016). Splitting atoms: the Endocrine Society guideline for the management of primary aldosteronism. Lancet Diabetes Endocrinol vol. 4, (10) 805-807.
Petruzzelli M, Taylor KP, Koo B, Brown MJ(2016). Telling Tails: Very High Plasma Renin Levels Prompt the Diagnosis of Renal Artery Stenosis, Despite Initial Negative Imaging. Hypertension vol. 68, (1) 11-16.
Xie CB, Shaikh LH, Garg S, Tanriver G, Teo AED, Zhou J, Maniero C, Zhao W et al.(2016). Regulation of aldosterone secretion by Cav1.3. Sci Rep vol. 6,
Teo AED, Brown MJ(2016). Pregnancy, Primary Aldosteronism, and Somatic CTNNB1 Mutations. N Engl J Med vol. 374, (15)
Brown MJ, Williams B, Morant SV, Webb DJ, Caulfield MJ, Cruickshank JK, Ford I, McInnes G et al.(2016). Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol vol. 4, (2) 136-147.
Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK et al.(2015). Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet vol. 386, (10008) 2059-2068.
Return to top